FDA Approves New Treatment for Parkinson's Disease

The U.S. Food and Drug Administration (FDA) approved a new oral medication for adults with Parkinson's disease on September 28, 2026. Called JUVMO (tavapadon), the medication was developed by pharmaceutical company AbbVie. It is the first approved treatment that selectively targets dopamine D1/D5 receptors, offering an alternative for controlling the motor symptoms of this neurological disease. The medication is taken once daily and can be used alone or in combination with levodopa, one of the most widely used treatments for Parkinson's. Its approval was based on results from the TEMPO clinical trial program, which demonstrated significant improvements in patients' ability to perform everyday activities and control their movements. Although it is not a cure, it introduces a new option for people facing the challenges of living with this progressive disease.

Living with Parkinson's presents constant challenges, especially when patients must adjust their medication schedules to accommodate fluctuations in motor symptoms throughout the day. Parkinson's disease is a chronic neurodegenerative disorder of the central nervous system that primarily affects movement and worsens over time. It occurs when neurons in a specific area of the brain deteriorate or die, reducing the production of dopamine, a chemical essential for coordinating movement. The nervous system is a complex network of cells that controls numerous bodily functions, and reduced dopamine levels interfere with the signals needed to perform normal movements. According to estimates cited by AbbVie, more than 11 million people worldwide are living with Parkinson's.

Symptoms usually develop gradually and may begin with a barely noticeable tremor in one hand, foot, or the jaw. Although tremors are common, the disease can also cause muscle stiffness, slowed movements, and balance problems that increase the risk of falls. In the early stages, facial expressions may become less pronounced, the arms may stop swinging naturally while walking, and speech may become softer or more difficult to understand. As the disease progresses, these difficulties can affect activities as simple as getting dressed, eating, walking, or maintaining balance. The severity of symptoms varies among patients and can change throughout the same day.

The exact causes of Parkinson's remain unknown, although research indicates that genetic and environmental factors play a role. There is currently no cure, but medications, physical therapy, and certain surgical procedures can help control symptoms and improve quality of life. Surgical options include deep brain stimulation, which uses electrical impulses to modify activity in specific regions of the brain and can relieve certain motor problems in selected patients. Levodopa remains one of the primary treatments because the body converts it into dopamine, partially compensating for reduced levels of this chemical. However, over time, many patients need to adjust their doses and how frequently they take the medication to maintain control of their movements.

One of the greatest treatment challenges involves motor fluctuations, which cause periods when medications work effectively and others when symptoms return. During so-called ON periods, patients can move more easily and carry out their usual activities, while during OFF periods, they may again experience tremors, stiffness, or slowed movement. Dyskinesias may also develop, producing abnormal involuntary movements that include jerking, twisting, or movements that are difficult to control. These complications can significantly interfere with daily life and require treatment adjustments. For this reason, researchers continue searching for medications that can provide more consistent symptom control.

JUVMO introduces an innovative pharmaceutical alternative because it acts on the dopamine system through a mechanism different from that of other medications used to treat Parkinson's. Its active ingredient, tavapadon, is a selective dopamine D1/D5 receptor agonist, meaning it stimulates these receptors by mimicking certain effects of dopamine. Other traditional dopamine agonists, such as ropinirole and pramipexole, primarily act on D2/D3 receptors. This difference offers another way to address motor symptoms, although it does not mean the new medication has been proven superior or safer than all existing treatments. AbbVie added tavapadon to its portfolio through its acquisition of Cerevel Therapeutics, completed in 2024.

FDA authorization was based on results from the Phase 3 TEMPO clinical trial program, which evaluated the medication's effectiveness and safety in people with Parkinson's at different stages of the disease. In the TEMPO-1 and TEMPO-2 studies, conducted with patients who were not yet taking levodopa, JUVMO produced statistically significant improvements compared with placebo in activities of daily living after 26 weeks of treatment. Researchers used the MDS-UPDRS scale, an assessment tool developed by the Movement Disorder Society to measure motor and nonmotor symptoms of Parkinson's and their effects on everyday life. The activities evaluated included dressing, eating, maintaining personal hygiene, and performing routine movements. The results demonstrated benefits in symptom control, although individual responses may vary.

The TEMPO-3 study also showed favorable results in patients who were already taking levodopa and experiencing motor fluctuations. After 26 weeks, those receiving JUVMO with levodopa gained an average of 1.7 additional hours per day of ON time without troublesome dyskinesia, compared with 0.6 hours among those receiving placebo with levodopa. Daily OFF time decreased by 1.9 hours in the JUVMO group, compared with 0.9 hours in the placebo group. These results indicate that the medication can provide longer periods of functional mobility without involuntary movements that significantly interfere with activities. Sustained benefits were also observed in some participants during an extension of the clinical program, although those findings must be interpreted in light of the limitations of follow-up studies.

As with other Parkinson's medications, JUVMO can cause side effects that must be considered before starting treatment. Clinical trials identified nausea, headache, dizziness, fatigue, changes in taste, vomiting, dry mouth, and anxiety among the more common reactions when the medication was used without levodopa. When combined with levodopa, dyskinesias, hallucinations, and orthostatic hypotension were also observed. Orthostatic hypotension is a drop in blood pressure when standing after sitting or lying down, which can cause dizziness or fainting. The medication can also cause or worsen involuntary movements and lead to impulse-control problems, including compulsive behaviors involving shopping, gambling, or eating. For these reasons, treatment requires medical supervision and dosage adjustments based on each patient's response and tolerance.

JUVMO is taken orally once daily, with or without food, and treatment begins with low doses that are gradually increased according to medical instructions. The usual maintenance dose is 5 milligrams daily, although it may be increased to a maximum of 15 milligrams depending on the patient's clinical response and side effects. The FDA authorized its use in adults, both as a standalone treatment and as an addition to levodopa. AbbVie announced that it expected to begin distribution in the United States during October 2026, while approval in other countries depends on the procedures of their respective health authorities. Actual availability and access conditions may vary depending on the market and insurance coverage.

The approval of JUVMO represents an advance in the options available to control Parkinson's symptoms, particularly for patients who need to improve mobility or reduce fluctuations that affect their daily activities. However, the medication does not stop neuronal degeneration and has not been shown to cure the disease, so its usefulness must be evaluated alongside existing treatments and each person's individual needs. Results from the TEMPO program provide evidence of clinical benefits, but they also demonstrate the importance of monitoring side effects and continuing research into its long-term safety and effectiveness. For people living with Parkinson's, having another treatment option may offer greater flexibility in adapting therapy as their symptoms evolve. While research continues to seek ways to slow or prevent the disease, improving patients' ability to function in everyday life remains one of medicine's most important goals.

Viviana Cetola

Life News Today